The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic ...
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...
Zacks.com on MSN1d
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by ParatekOptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program ...
Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...
5d
Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Zai Lab Limited (NASDAQ:ZLAB – Free Report) during the fourth quarter, HoldingsChannel reports. The firm purchased 63,909 ...
Ceftobiprole was turned down by the FDA in 2009 for ABSSSI when the drug was partnered with Johnson & Johnson’s Janssen Cilag unit. It has subsequently been approved as Zevtera or Mabelio in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback